James Xu

536 total citations
11 papers, 332 citations indexed

About

James Xu is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James Xu has authored 11 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James Xu's work include Cancer Immunotherapy and Biomarkers (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Renal cell carcinoma treatment (3 papers). James Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Renal cell carcinoma treatment (3 papers). James Xu collaborates with scholars based in United States. James Xu's co-authors include Amna Ibrahim, Richard Pazdur, Shenghui Tang, V. Ellen Maher, Rajeshwari Sridhara, Chana Weinstock, Julia A. Beaver, Laura L. Fernandes, Daniel L. Suzman and Michael H. Brave and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

James Xu

10 papers receiving 329 citations

Peers

James Xu
Sarah Caulfield United States
Yvonne Ang Singapore
Meagan S. Barbee United States
Elizabeth Panora United States
Eriko Murakami Japan
Giulia Grizzi Italy
Jia-Wei Lv China
Pauline Corbaux France
Francisco Aparisi Spain
Olivia Wilkins United States
Sarah Caulfield United States
James Xu
Citations per year, relative to James Xu James Xu (= 1×) peers Sarah Caulfield

Countries citing papers authored by James Xu

Since Specialization
Citations

This map shows the geographic impact of James Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Xu more than expected).

Fields of papers citing papers by James Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Xu. The network helps show where James Xu may publish in the future.

Co-authorship network of co-authors of James Xu

This figure shows the co-authorship network connecting the top 25 collaborators of James Xu. A scholar is included among the top collaborators of James Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Xu. James Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Xu, James, Mark Benson, Jennifer Weiss, et al.. (2023). Development of a Low-Cost Gastroscope Prototype (GP) for Potential Cost-Effective Gastric Cancer Screening in Prevalent Regions. SHILAP Revista de lepidopterología. 14(1). 22–29.
2.
Weinstock, Chana, Laura L. Fernandes, Elaine Chang, et al.. (2020). Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 38(15_suppl). 5045–5045. 2 indexed citations
3.
Brewer, Jamie R., Elaine Chang, Sundeep Agrawal, et al.. (2020). Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. Clinical Cancer Research. 26(24). 6406–6411. 6 indexed citations
4.
Weinstock, Chana, V. Ellen Maher, Laura L. Fernandes, et al.. (2019). An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.. Journal of Clinical Oncology. 37(15_suppl). 4549–4549. 1 indexed citations
5.
Maher, V. Ellen, Laura L. Fernandes, Chana Weinstock, et al.. (2019). Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. Journal of Clinical Oncology. 37(30). 2730–2737. 231 indexed citations
6.
Ison, Gwynn, V. Ellen Maher, Chana Weinstock, et al.. (2019). Causes of patient ineligibility in clinical trials of metastatic urothelial cancer.. Journal of Clinical Oncology. 37(15_suppl). 4556–4556. 1 indexed citations
7.
Weinstock, Chana, V. Ellen Maher, Laura L. Fernandes, et al.. (2019). Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.. Journal of Clinical Oncology. 37(15_suppl). 4557–4557. 4 indexed citations
8.
Xu, James, et al.. (2018). Dynamic Visual Feedback During Junctional Tourniquet Training. Journal of Surgical Research. 233. 444–452. 3 indexed citations
9.
Xu, James, V. Ellen Maher, Lijun Zhang, et al.. (2017). FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. The Oncologist. 22(3). 311–317. 77 indexed citations
10.
11.
Weinstock, Chana, V. Ellen Maher, Lijun Zhang, et al.. (2016). FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.. Journal of Clinical Oncology. 34(15_suppl). 4508–4508. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Caulfield Breakdown of academic impact, for papers by Yvonne Ang Breakdown of academic impact, for papers by Meagan S. Barbee Breakdown of academic impact, for papers by Elizabeth Panora Breakdown of academic impact, for papers by Eriko Murakami Breakdown of academic impact, for papers by Giulia Grizzi Breakdown of academic impact, for papers by Jia-Wei Lv Breakdown of academic impact, for papers by Pauline Corbaux Breakdown of academic impact, for papers by Francisco Aparisi Breakdown of academic impact, for papers by Olivia Wilkins
Rankless by CCL
2026